IperionX (ASX:IPX) requested that its securities be placed under a trading halt pending the release of a response regarding a report released by hedge fund Spruce Point Capital Management on Wednesday, according to a Thursday Australian bourse filing.
It requested that the trading halt remain in place until either the release of the response or the start of trading on Nov. 17.
Spruce Point said that it conducted a forensic review of IperionX, concluding that it "faces significant challenges in commercial efforts that may not be fully reflected in its valuation," while also expressing concerns "with the accuracy of its financial reporting."
IperionX's Hydrogen Assisted Metallothermic Reduction (HAMR) process is not likely to reshape the industry or displace the existing Kroll process for producing titanium, per the report. It put the "downside risk" for the stock at between 70% and 95%.
Comments